Roche puts down $75M to sign on as new part­ner for Ion­is' dry AMD drug, fol­low­ing Hunt­ing­ton's deal

Io­n­is is team­ing up with Roche again, this time to de­vel­op an an­ti­sense drug for dry AMD with an up­front pay­ment of $75 mil­lion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.